clinical trial · NCT07141004
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
Johnson & Johnson Private Limited·phase4·recruiting·n = 100
Arthritis, PsoriaticGuselkumab
brief summary
The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.
started
Aug 12, 2025
primary completion
Jun 5, 2027
completion
Sep 11, 2027
last updated
Jul 31, 2026
official title
A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol